By a News Reporter-Staff News Editor at Journal of Technology -- Data detailed on Immunology have been presented. According to news reporting originating from Braga, Portugal, by VerticalNews correspondents, research stated, "N-glycosylation is one of the most crucial parameters affecting the biological activity of therapeutic monoclonal antibodies (mAbs), and should therefore be closely monitored and controlled to guarantee a consistent and high-quality product in biopharmaceutical processes. In the present work, the effect of the time-consuming step of gradual cell adaptation to serum-free conditions on the glycosylation profile of a mAb produced by CHO-K1 cells was evaluated."
Our news editors obtained a quote from the research from the University of Minho, "High-performance liquid chromatography analysis revealed important changes in mAb glycosylation patterns in all steps of serum reduction. These changes could be grouped in two distinct phases of the process of adaptation: middle (2.5 to 0.15% serum) and final (0.075 and 0% serum). For intermediate levels of serum, a desirable increase of galactosylation and decrease of fucosylation, but an undesirable increase in sialylation were observed; while the inverse was obtained at the final stages of adaptation. These divergences may be related to the reduction of serum supplementation, to variations in the levels of cell density and viability achieved at these stages, and to the natural shift of the cell growth mode during adaptation from adherent to suspended."
According to the news editors, the research concluded: "The divergent glycan profiles obtained in this study demonstrate a strong influence of the adaptation process on mAb glycosylation, suggesting that control and monitoring of product quality should be implemented at the early stages of process development."
For more information on this research see: The impact of cell adaptation to serum-free conditions on the glycosylation profile of a monoclonal antibody produced by Chinese hamster ovary cells. New Biotechnology, 2013;30(5):563-72. (Elsevier - www.elsevier.com; New Biotechnology - www.elsevier.com/wps/product/cws_home/713354)
The news editors report that additional information may be obtained by contacting A.R. Costa, IBB-Institute for Biotechnology and Bioengineering, Centre of Biological Engineering, University of Minho, Campus de Gualtar 4710-057, Braga, Portugal. Additional authors for this research include J. Withers, M.E. Rodrigues, N. McLoughlin, M. Henriques, R. Oliveira, P.M. Rudd and J. Azeredo.
Keywords for this news article include: Antibodies, Braga, Europe, Therapy, Portugal, Immunology, Blood Proteins, Immunoglobulins.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC